- Home
- HHH vs ALKS Comparison
HHH vs ALKS Comparison
Compare HHH & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHH
- ALKS
- Stock Information
- Founded
- HHH 2010
- ALKS 1987
- Country
- HHH United States
- ALKS Ireland
- Employees
- HHH N/A
- ALKS N/A
- Industry
- HHH Real Estate Investment Trusts
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- HHH Real Estate
- ALKS Health Care
- Exchange
- HHH Nasdaq
- ALKS Nasdaq
- Market Cap
- HHH 4.7B
- ALKS 5.0B
- IPO Year
- HHH N/A
- ALKS 1991
- Fundamental
- Price
- HHH $82.25
- ALKS $29.74
- Analyst Decision
- HHH Buy
- ALKS Strong Buy
- Analyst Count
- HHH 2
- ALKS 14
- Target Price
- HHH $90.00
- ALKS $42.21
- AVG Volume (30 Days)
- HHH 332.5K
- ALKS 2.1M
- Earning Date
- HHH 11-10-2025
- ALKS 10-28-2025
- Dividend Yield
- HHH N/A
- ALKS N/A
- EPS Growth
- HHH N/A
- ALKS 21.99
- EPS
- HHH 4.43
- ALKS 2.08
- Revenue
- HHH $1,770,945,000.00
- ALKS $1,505,296,000.00
- Revenue This Year
- HHH N/A
- ALKS N/A
- Revenue Next Year
- HHH $21.07
- ALKS $1.59
- P/E Ratio
- HHH $16.25
- ALKS $14.36
- Revenue Growth
- HHH 80.45
- ALKS N/A
- 52 Week Low
- HHH $61.41
- ALKS $25.17
- 52 Week High
- HHH $87.77
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- HHH 56.78
- ALKS 46.39
- Support Level
- HHH $80.24
- ALKS $29.94
- Resistance Level
- HHH $81.71
- ALKS $32.02
- Average True Range (ATR)
- HHH 1.53
- ALKS 1.07
- MACD
- HHH -0.21
- ALKS -0.23
- Stochastic Oscillator
- HHH 57.65
- ALKS 7.32
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.